All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
María-Victoria MateosMaria-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, talks to the MM Hub at ASCO 2019 about the phase III COLUMBA results. The study reports that subcutaneous administration of daratumumab (dara-SC) is non-inferior to intravenous administration (dara-IV). In a satisfaction questionnaire, patients reported a more favorable experience with dara-SC making it an attractive and viable option, both in terms of efficacy, and patient quality-of-life. Professor Mateos added that she believes daratumumab will be mainly administered subcutaneously, in the near future.
Maria-Victoria Mateos kindly gave her interview in Spanish, with the title: Resultados del ensayo randomizado fase III COLUMBA.
Highlights of the randomized phase III COLUMBA study